λ-Carrageenan improves the antitumor effect of dendritic cellbased vaccine

  • Oncotarget. 2017 May 2;8(18):29996-30007. doi: 10.18632/oncotarget.15610.
Jinyao Li  1  2  3 ,  Adila Aipire  2 ,  Jinyu Li  2 ,  Hongge Zhu  1 ,  Yanping Wang  4 ,  Wenjia Guo  1 ,  Xiaoqin Li  1 ,  Jia Yang  1 ,  Chunling Liu  1
Affiliations
  • 1. Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China.
  • 2. College of Life Science and Technology, Xinjiang University, Urumqi 830046, China.
  • 3. XinJiang DingJu Biotech CO., LTD, Urumqi 830000, China.
  • 4. Bayin Guoleng Vocational and Technical College, Korla 841000, China.
PMID: 28404904 DOI: 10.18632/oncotarget.15610
Abstract

In this study, we investigated the effect of λ-carrageenan on the maturation and function of dendritic cells (DCs) and its Adjuvant effect on DC-based vaccine. We found that λ-carrageenan dose-dependently decreased the endocytosis of DCs, promoted DC maturation and increased cytokine production through TLR4 mediated signaling pathway. λ-carrageenan treatment also enhanced the ability of DCs in the stimulating allogenic splenocyte proliferation. In TC-1 tumor mouse model, HPV peptides pulsed λ-carrageenan-DC (HPV-CGN-DC) significantly inhibited tumor growth compared with control group. The frequencies of CD4+ and CD8+ T cells in spleens of tumor mice and their activation status were significantly increased in HPV-CGN-DC group, but the frequencies of natural regulatory T cells and CD11b+Gr-1+ cells were significantly decreased. Further, HPV-CGN-DC induced strong CD8+ T cell responses, which are negatively correlated with tumor volumes. The results suggested that λ-carrageenan promoted DC maturation through TLR4 signaling pathway and could be used as the Adjuvant in DC-based vaccines.

Keywords
TLR4; cancer immunotherapy; cellular responses; dendritic cell-based vaccine; λ-carrageenan.
Products